Cat.No：GM-87846AB

Product：Anti-CEACAM5-DM4(Dar4)[Tusamitamab ravtansine]

GM-87846AB-100       100μg

GM-87846AB-1mg      1mg

Expression System                         CHO

Purity                                                    >95% as determined by SDS-PAGE

Aggregation                                       < 5% as determined by SEC-HPLC

Drug-to-Antibody Ratio (DAR)  3.0-4.0

Endotoxin                                            <1 EU/mg

Sterility                                                 0.22 μm Filtered

Target                                                    CEACAM5

Clone                                                     Tusamitamab ravtansine

Alternative Names                          CD66e, CEA

Source/lsotype                                 Monoclonal Human IgG1, kappa

Application                                         Positive control of Cytotoxicity Assay

Description                                         Tusamitamab ravtansine (SAR408701) is a novel antibody-drug conjugate (ADC) targeting CEA (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5, also known as CD66e). The drug specifically binds to CEA-expressing tumor cells through its chimeric monoclonal antibody and is subsequently internalized into the cells, where it releases the conjugated cytotoxic molecule DM4 (ravtansine, a derivative of an anti-microtubule agent). DM4 disrupts microtubule function, blocks mitosis, and induces tumor cell apoptosis. Tusamitamab ravtansine combines the benefits of targeted therapy and chemotherapy, enhancing treatment precision while significantly reducing systemic toxicity and off-target effects.

Formulation                                         Phosphate-buffered solution, pH 7.2-7.4.

Storage temp.                                     Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.